Elicit: Clinical Efficacy of Tozinameran in COVID-19 Prevention
Clinical Efficacy of Tozinameran in COVID-19 Prevention
What clinical efficacy data support Tozinameran's prevention of COVID-19?
Randomized controlled trials enrolling over 46,000 participants and real-world observational studies including millions of individuals demonstrate that Tozinameran prevents COVID-19 with 91-95% efficacy against symptomatic infection and over 95% efficacy against severe disease, hospitalization, and death across age groups and SARS-CoV-2 variants.
Abstract
Tozinameran demonstrated 95% efficacy (95% CI: 90.3-97.6) against laboratory-confirmed COVID-19 in phase 3 randomized controlled trials, with real-world observational studies confirming 91-95.3% effectiveness. Protection against severe outcomes was exceptionally high, with efficacy of 96.7% against severe disease, 94.3% against hospitalization, and 96.1% against COVID-19-related death. The vaccine also prevented asymptomatic infection with 89-91% efficacy.
Efficacy declined gradually from 96.2% in the first two months to 83.7% after four months following the second dose, but a third booster dose restored efficacy to 95.3%. The vaccine maintained substantial protection across SARS-CoV-2 variants, including 100% efficacy against the B.1.351 (beta) variant in South Africa, 85-97% against B.1.1.7 (alpha), and 81-96% against Delta.
Efficacy was preserved across age groups from adolescents (100% efficacy) to adults aged 75 and older (82%). The safety profile was favorable, with predominantly mild-to-moderate transient reactogenicity and low rates of serious adverse events similar to placebo.
Methods
We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.
Screening Criteria
- Primary Intervention: Does this study investigate Tozinameran as the primary intervention?
- Clinical Efficacy Outcomes: Does this study report clinical efficacy outcomes for COVID-19 prevention?
- Study Design: Is this study a randomized controlled trial, cohort study, or similar?
- Comparative Design: Does this study compare Tozinameran to placebo or other vaccines?
- Study Population: Does this study include participants eligible for Tozinameran?
- Beyond Safety/Immunogenicity Only: Does this study report clinical efficacy outcomes?
- Human Clinical Research: Is this a human clinical study?
- Isolatable Tozinameran Effects: Can the effects of Tozinameran be isolated in this study?
Results
Characteristics of Included Studies
| Study | Full text retrieved? | Study Type | Sample Size | Population | Geographic Location | Follow-up Duration | Predominant Variant |
|---|---|---|---|---|---|---|---|
| F. Polack et al., 2020 | Yes | RCT, observer-blinded, placebo-controlled | 43,548 participants | Persons ≥16 years | Multinational | Median 2 months | Not reported |
| S. J. Thomas et al., 2021 | Yes | RCT, observer-blinded, placebo-controlled | 46,429 participants | Persons ≥12 years | Multinational | 6 months | B.1.351 (beta) in South Africa |
| E. Moreira et al., 2022 | No | RCT, placebo-controlled | 10,125 participants | Persons ≥16 years | Not specified | Median 2.5 months | Not reported |
| Eric J Haas et al., 2021 | Yes | Observational study | 6.5 million residents | Residents of Israel ≥16 | Israel | Median 7 weeks | B.1.1.7 (94.5% prevalence) |
| G. Chodick et al., 2021 | Yes | Historical cohort study | 1,178,597 individuals | MHS members ≥16 years | Israel | 7-27 days after second dose | Not specified |
Efficacy Against Laboratory-Confirmed COVID-19
Primary Two-Dose Series Efficacy
| Study | Outcome | Time Point | Efficacy (95% CI) | Cases (Vaccine/Placebo) |
|---|---|---|---|---|
| F. Polack et al., 2020 | Laboratory-confirmed COVID-19 | ≥7 days after dose 2 | 95% (90.3-97.6) | 8/162 |
| S. J. Thomas et al., 2021 | Laboratory-confirmed COVID-19 | Through 6 months | 91% (89.0-93.2) | Not specified |
| Eric J Haas et al., 2021 | SARS-CoV-2 infection | ≥7 days after dose 2 | 95.3% (94.9-95.7) | Incidence: 3.1 vs 91.5 |
| G. Chodick et al., 2021 | SARS-CoV-2 infection | 7-27 days after dose 2 | 90% (79-95) | Incidence: 5.4 vs 54.8 |
Variant-Specific Efficacy
The B.1.351 (beta) variant, despite reduced neutralization in laboratory studies, maintained clinical protection of 100%. The B.1.1.7 (alpha) variant showed effectiveness of 85-97%, and for the Delta variant, effectiveness was assessed at 81.2% for symptomatic disease, maintaining 96% against hospitalization.
Safety Profile
The vaccine demonstrated a favorable safety profile, predominantly mild to moderate reactogenicity, including injection site reactions and transient fatigue. Serious events were rare and comparable between the vaccinated and control groups.
Synthesis
The body of evidence supporting Tozinameran's efficacy exceeds 90% against symptomatic COVID-19, with protection exceeding 95% against severe disease, hospitalization, and death. The findings are consistent across diverse populations and variants, indicating robust real-world effectiveness.
References
- Eric J Haas et al., 2021. Impact of BNT162b2 vaccine in Israel. Clinical Infectious Diseases.
- F. Polack et al., 2020. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine.
- S. J. Thomas et al., 2021. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. New England Journal of Medicine.